Sumary of Pfizer says early COVID-19 vaccine data suggests its shots may be 90 per cent effective. But that figure could change:
- Pfizer says an early peek at its vaccine data suggests the shots may be 90 per cent effective at preventing COVID-19, indicating the company is on track to file an emergency use application later this month with US regulators..
- The early analysis looked at just 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the US and five other countries Pfizer cautioned the initial protection rate might change by the time the study ends Authorities stress it’s unlikely any vaccine will arrive before the end of the year and limited initial supplies will be rationed This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the US and five other countries..
- Authorities have stressed it’s unlikely any vaccine will arrive much before the end of the year, and limited initial supplies will be rationed..
- The shots made by Pfizer and its German partner BioNTech are among 10 possible vaccine candidates in late-stage testing around the world — four of them so far in huge studies in the US..
- Lessons from the last big vaccine race Billions are being poured into the race to find a coronavirus vaccine, with the winner owning a powerful political tool..
- Volunteers in the final-stage studies, and the researchers, don’t know who received the real vaccine or a dummy shot..
- Pfizer doesn’t plan to stop its study until it records 164 infections among all the volunteers, a number that the FDA has agreed is enough to tell how well the vaccine is working..
- The FDA’s scientific advisers worry that allowing emergency use of a COVID-19 vaccine could damage confidence in the shots and make it harder to ever find out how well they really work.(Pixabay:…